To describe the use of topical recombinant collagen in postprocedural care following fractional radiofrequency microneedling (FRM) for nonsurgical facelift, in the context of the absence of established postprocedural care protocols.
Approach:
Case Presentation: Two 40-year-old female patients with Fitzpatrick skin type IV and facial laxity underwent FRM and received topical recombinant collagen immediately post-treatment. Clinical assessments were conducted before, immediately after, and 1-2 hours post-treatment, with standardized clinical photography performed under consistent lighting.
Key Findings:
Topical recombinant collagen application was associated with a significant reduction in facial edema and erythema within 1-2 hours post-treatment.
Patients reported immediate relief from skin discomfort and burning sensation after collagen application.
No adverse events or side effects were reported.
Interpretation:
Limitations:
Only two patients were included with short-term follow-up.
No control group for comparison.
Lack of standardized scoring systems for erythema, swelling, or patient-reported outcomes.
Conclusion:
Further evaluation in prospective clinical trials is warranted to assess the role of topical recombinant collagen in postprocedural care following FRM.
